Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection

Parasitology International

Volumn 62, Issue 3, 2013, Pages 293-299

  Strauss, Mariana ^a,b   Lo Presti, M Silvina ^a,b   Bazán, Paula Carolina ^a,b   Baez, Alejandra ^a,b   Fauro, Romina ^a,b   Esteves, Blanca ^a,b   Sanchez Negrete, Olga ^c   Cremonezzi, David ^a   Paglini Oliva, Patricia A ^a,b   Rivarola, H Walter ^a,b,d  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b Unidad Ejecutora   (Argentina)

^c UNIVERSIDAD NACIONAL DE SALTA   (Argentina)

^d Universidad Nacional de La Rioja   (Argentina)

Author keywords

Acute phase; American trypanosomiasis; Antitrypanosomal drugs; Chemotherapy

Indexed keywords

BENZNIDAZOLE; CLOMIPRAMINE; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CELL DEATH; CHAGAS DISEASE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAPHY; FEMALE; HEART MUSCLE; HISTOPATHOLOGY; INFLAMMATORY CELL; KIDNEY; LIVER; LOW DRUG DOSE; MALE; MORTALITY; MOUSE; MUSCLE; NONHUMAN; PARASITEMIA; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; SKELETAL MUSCLE; SURVIVAL; TRYPANOSOMA CRUZI; ANIMAL; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; INTESTINE; PATHOLOGY;

MUS; TRYPANOSOMA CRUZI;

ANIMALS; CHAGAS DISEASE; CLOMIPRAMINE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; FEMALE; INTESTINES; KIDNEY; LIVER; MALE; MICE; MUSCLE, SKELETAL; MYOCARDIUM; NITROIMIDAZOLES; PARASITEMIA; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84875388133     PISSN: 13835769     EISSN: 18730329     Source Type: Journal    
DOI: 10.1016/j.parint.2013.02.004     Document Type: Article

References (41)

1. Guhl F., Lanzdins-Helds J.K. Report on Chagas disease. World Health Organization on behalf of the special programme for research and training in tropical diseases 2007, WHO, Geneva, Switzerland.
2. Albajar-Viñas P., Jannin J. The hidden Chagas disease burden in Europe. Euro Surveillance 2011, 16-38.
3. Soeiro M.N., de Castro S.L. Trypanosoma cruzi targets for new chemotherapeutic approaches. Expert Opinion on Therapeutic Targets 2009, 13:105-121.
4. Moreno M., D'ávila D.A., Silva M.N., Galvão L.M.C., Macedo A.M., Chiari E., et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Memórias do Instituto Oswaldo Cruz 2010, 105:918-924.
5. Toledo M.J., Bahia M.T., Veloso V.M., Carneiro C.M., Machado-Coelho G.L.L., Alves C.F., et al. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes. The Journal of Antimicrobial Chemotherapy 2004, 53:1045-1053.
6. Caldas I.S., Talvani A., Caldas S., Carneiro C.M., de Lara M., de Matta Guedes P.M., et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitology Research 2008, 103:413-421.
7. Villarreal D., Barnabe C., Sereno D., Tibayrenc M. Lack of correlation between in vitro susceptibility to benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease. Experimental Parasitology 2004, 108:24-31.
8. Stoppani A.O. The chemotherapy of Chagas disease. Medicina (B Aires) 1999, 59(Suppl. 2):147-165.
9. Gobbi P., Baez A., Lo Presti M.S., Fernandez A.R., Enders J.E., Fretes R., et al. Association of clomipramine and allopurinol for the treatment of the experimental infection with Trypanosoma cruzi. Parasitology Research 2010, 107:1279-1283.
10. Rivarola H.W., Bustamante J.M., Lo Presti M.S., et al. Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area. Experimental Parasitology 2005, 111:80-86.
11. Bustamante J.M., Rivarola H.W., Fernández A.R., Enders J.E., Fretes R., De Luca d' Oro G., et al. Trypanosoma cruzi reinfections provoke synergistic effect and cardiac β-adrenergic receptors' dysfunction in the acute phase of experimental Chagas' disease. Experimental Parasitology 2003, 103:136-142.
12. Urbina J.A., Docampo R. Specific chemotherapy of Chagas disease, controversies and advances. Trends in Parasitology 2003, 19:495-501.
13. Villasana M., Ochoa G., Aguilar S. Modeling and optimization of combined cytostatic and cytotoxic cancer chemotherapy. Artificial Intelligence in Medicine 2010, 50(3):163-173.
14. Radloff P.D., Philipps J. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511-1514.
15. Araújo M.S.S., Martins-Filho O.A., Pereira M.E.S., Brener Z. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. The Journal of Antimicrobial Chemotherapy 2000, 45:819-824.
16. Zingales B., Andrade S.G., Briones M.R., Campbell D.A., Chiari E., Fernandes O., et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Memórias do Instituto Oswaldo Cruz 2009, 104:1051-1054.
17. Rottenberg M., Cardoni R., Andersson R., Segura E., Örn A. Role of T helper/inducer cells as well as natural killer cells in the resistance to Trypanosoma cruzi infection. Scandinavian Journal of Immunology 1988, 28:573.
18. Committee for the update of the guide for the care and use of laboratory animals. Guide for the care and use of laboratory animals 2011, National Academies Press, Washington, D.C. 8th ed.
19. Sánchez Negrette O., Sánchez Valdéz F.J., Lacunza C.D., García Bustos M.F., Mora M.C., Uncos A.D., et al. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clinical and Vaccine Immunology 2008, 15:297-302.
20. Sambrook J., Russell D. Molecular cloning, a laboratory manual 2001, Cold spring harbord laboratory press, New York. 3rd ed.
21. Requena J., Jimenez-Ruiz A., Soto M., Lopez M.C., Alonso C. Characterization of highly repeated interspersed DNA secuence of Tripanosoma cruzi: its potencial use in diagnosis, and strain classification. Molecular and Biochemical Parasitology 1991, 51:271-280.
22. Peters N.S., Green C.R., Poole-Wilson P.A., Severes N.J. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993, 88:864-875.
23. Fabbro D.L., Streiger M.L., Arias E.D., Bizai M.L., del Barco M. Amicone NA Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21years: parasitological, serological and clinical evolution. Revista da Sociedade Brasileira de Medicina Tropical 2007, 40:1-10.
24. Viotti R., Vigliano C., Lococo B., Bertocchi G., Petti M., Alvarez M.G., et al. Long Term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment-a nonrandomized trial. Annals of Internal Medicine 2006, 144:724-734.
25. Gallerano R.R., Sosa R.R. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Revista de la Facultad de Ciencias Médicas de la Universidad Nac. de Córdoba 2000, 57:135-162.
26. Sánchez Negrette O., Sánchez Valdéz F.J., Lacunza C.D., García Bustos M.F., Mora M.C., Uncos A.D., et al. Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease. Clinical and Vaccine Immunology 2008, 15(2):297-302.
27. Pinazo M.J., Muñoz J., Posada E., López-Chejade P., Gállego M., Ayala E., et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrobial Agents and Chemotherapy 2010, 54(11):4896-4899.
28. Coura J.R., de Abreu L., Willcox H.P., Petana W. Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease in a field area with interrupted transmission. I. Preliminary evaluation. Revista da Sociedade Brasileira de Medicina Tropical 1997, 30:139-144.
29. de Pontes V.M., Souza Júnior A.S., Cruz F.M., Coelho H.L., Dias A.T., Coêlho I.C., et al. Reações adversas em pacientes com doença de Chagas tratados com benzonidazol, no Estado do Ceará. Revista da Sociedade Brasileira de Medicina Tropical 2010, 43(2):182-187.
30. Mejia A.M., Hall B.S., Taylor M.C., Gómez-Palacio A., Wilkinson S.R., Triana-Chávez O., et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. The Journal of Infectious Diseases 2012, 206(2):220-228.
31. Fabbro D., Velazquez E., Mendoza N., Streiger M., Arias E., Denner S., et al. F29 evaluation of ELISA as a marker of efficacy of etiological treatment of Chagas disease. Latin American Parasitology 2007, 62:103-111.
32. Schijman A.G., Altcheh J., Burgos J.M., Biancardi M., Bisio M., Levin M.J., et al. Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. The Journal of Antimicrobial Chemotherapy 2003, 52:441-449.
33. Zulantay I., Honores P., Solari A., Apta W., Ortiza S., Osunab A., et al. Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol. Diagnostic Microbiology and Infectious Disease 2004, 48:253-257.
34. Sánchez G., Coronado X., Zulantay I., Apt W., Gajardo M., Solari S., et al. Monitoring the efficacy of specific treatment in chronic Chagas disease by polymerase chain reaction and flow cytometry analysis. Parasite 2005, 12:353-357.
35. Britto C.C. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Memórias do Instituto Oswaldo Cruz 2009, 104(Suppl. I):122-135.
36. Rivarola H.W., Fernández A.R., Enders J.E., Fretes R., Gea S., Paglini-Oliva P., et al. Effects of clomipramine on Trypanosoma cruzi infection in mice. Transactions of the Royal Society of Tropical Medicine and Hygiene 2001, 95:1-5.
37. Bazán P.C., Lo Presti M.S., Rivarola H.W., Triquell M.F., Fretes R., Fernandéz A.R., et al. Chemotherapy of chronic indeterminate Chagas disease. A novel approach to treatment. Parasitology Research 2008, 103:663-669.
38. Human Chagasic heart disease - pathologic aspects and pathogenesis [15 May 2012, date last accessed]. http://www.fiocruz.br/chagas_esp/cgi/cgilua.exe/sys/start.htm?sid=94.
39. Biolo A., Ribeiro A.L., Clausell N. Chagas cardiomyopathy - where do we stand after a hundred years?. Progress in Cardiovascular Diseases 2010, 52:300-316.
40. Rossi M.A., Tanowitz H.B., Malvestio L.M., Celes M.R., Campos E.C., Blefari V., et al. Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms. PLoS Neglected Tropical Diseases 2010, 4(8):e674.
41. Garcia S., Ramos C., Senra J., Vilas-Boas F., Rodrigues M.M., Campos-de-Carvalho A.C., et al. Treatment with benznidazole during the chronic phase of Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 2005, 49:1521-1528.